Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CTMX |
---|---|---|
09:32 ET | 35774 | 1.76 |
09:34 ET | 2888 | 1.755 |
09:36 ET | 35066 | 1.75 |
09:38 ET | 4828 | 1.7594 |
09:39 ET | 1200 | 1.75 |
09:41 ET | 5700 | 1.75 |
09:43 ET | 3155 | 1.75 |
09:45 ET | 46566 | 1.765 |
09:48 ET | 5643 | 1.77 |
09:50 ET | 750 | 1.7739 |
09:52 ET | 16818 | 1.765 |
09:54 ET | 7264 | 1.76 |
09:56 ET | 450 | 1.76 |
09:57 ET | 4301 | 1.76 |
09:59 ET | 14499 | 1.76 |
10:01 ET | 1657 | 1.76 |
10:03 ET | 2500 | 1.755 |
10:06 ET | 925 | 1.7583 |
10:08 ET | 300 | 1.76 |
10:10 ET | 7001 | 1.74 |
10:12 ET | 3769 | 1.75 |
10:14 ET | 3833 | 1.755 |
10:15 ET | 300 | 1.76 |
10:17 ET | 2300 | 1.76 |
10:19 ET | 7072 | 1.7589 |
10:21 ET | 14478 | 1.755 |
10:24 ET | 5976 | 1.7584 |
10:26 ET | 100 | 1.75 |
10:28 ET | 200 | 1.755 |
10:30 ET | 41464 | 1.7493 |
10:32 ET | 100 | 1.745 |
10:33 ET | 3896 | 1.745 |
10:35 ET | 600 | 1.75 |
10:37 ET | 7788 | 1.75 |
10:39 ET | 900 | 1.755 |
10:42 ET | 667 | 1.7506 |
10:44 ET | 800 | 1.755 |
10:46 ET | 900 | 1.755 |
10:48 ET | 2618 | 1.755 |
10:50 ET | 1368 | 1.75 |
10:51 ET | 1746 | 1.76 |
10:53 ET | 300 | 1.755 |
10:55 ET | 400 | 1.755 |
10:57 ET | 510 | 1.75 |
11:00 ET | 700 | 1.755 |
11:02 ET | 1877 | 1.755 |
11:04 ET | 1400 | 1.75 |
11:06 ET | 31477 | 1.735 |
11:08 ET | 1347 | 1.7394 |
11:09 ET | 17069 | 1.725 |
11:11 ET | 4259 | 1.73 |
11:13 ET | 3363 | 1.73 |
11:15 ET | 2187 | 1.725 |
11:18 ET | 8764 | 1.735 |
11:20 ET | 216 | 1.735 |
11:22 ET | 100 | 1.735 |
11:24 ET | 511 | 1.735 |
11:26 ET | 788 | 1.74 |
11:27 ET | 5867 | 1.7406 |
11:29 ET | 20111 | 1.74 |
11:31 ET | 100 | 1.735 |
11:33 ET | 200 | 1.735 |
11:36 ET | 300 | 1.74 |
11:38 ET | 1100 | 1.74 |
11:40 ET | 4452 | 1.745 |
11:44 ET | 1388 | 1.7433 |
11:45 ET | 619 | 1.745 |
11:49 ET | 3900 | 1.745 |
11:51 ET | 600 | 1.745 |
11:54 ET | 1863 | 1.7481 |
11:58 ET | 200 | 1.745 |
12:00 ET | 400 | 1.7485 |
12:02 ET | 500 | 1.75 |
12:03 ET | 300 | 1.75 |
12:05 ET | 446 | 1.75 |
12:07 ET | 200 | 1.75 |
12:09 ET | 200 | 1.75 |
12:12 ET | 1800 | 1.745 |
12:14 ET | 1000 | 1.75 |
12:16 ET | 1900 | 1.745 |
12:18 ET | 2239 | 1.745 |
12:20 ET | 200 | 1.745 |
12:21 ET | 500 | 1.745 |
12:23 ET | 840 | 1.745 |
12:25 ET | 1630 | 1.745 |
12:27 ET | 100 | 1.745 |
12:30 ET | 10779 | 1.745 |
12:32 ET | 3100 | 1.7478 |
12:34 ET | 400 | 1.745 |
12:36 ET | 1313 | 1.745 |
12:38 ET | 8920 | 1.74 |
12:39 ET | 300 | 1.735 |
12:43 ET | 19311 | 1.7201 |
12:45 ET | 700 | 1.725 |
12:48 ET | 100 | 1.725 |
12:50 ET | 200 | 1.725 |
12:52 ET | 300 | 1.725 |
12:54 ET | 500 | 1.725 |
12:56 ET | 400 | 1.73 |
12:57 ET | 1010 | 1.73 |
12:59 ET | 1400 | 1.73 |
01:01 ET | 5341 | 1.725 |
01:03 ET | 581 | 1.725 |
01:06 ET | 650 | 1.725 |
01:08 ET | 12114 | 1.715 |
01:10 ET | 5115 | 1.72 |
01:12 ET | 853 | 1.72 |
01:14 ET | 13317 | 1.7235 |
01:15 ET | 402 | 1.73 |
01:17 ET | 300 | 1.73 |
01:19 ET | 200 | 1.725 |
01:21 ET | 4803 | 1.73 |
01:24 ET | 11833 | 1.72 |
01:26 ET | 2600 | 1.7199 |
01:28 ET | 900 | 1.715 |
01:30 ET | 82620 | 1.715 |
01:32 ET | 1800 | 1.72 |
01:33 ET | 7000 | 1.71 |
01:35 ET | 200 | 1.715 |
01:37 ET | 2027 | 1.715 |
01:39 ET | 6007 | 1.7199 |
01:42 ET | 2564 | 1.715 |
01:44 ET | 31543 | 1.72 |
01:46 ET | 2547 | 1.7189 |
01:48 ET | 2300 | 1.7108 |
01:50 ET | 579 | 1.715 |
01:51 ET | 7356 | 1.715 |
01:53 ET | 12604 | 1.715 |
01:55 ET | 52671 | 1.7 |
01:57 ET | 41085 | 1.6901 |
02:00 ET | 56988 | 1.71 |
02:02 ET | 23336 | 1.7 |
02:04 ET | 2600 | 1.7 |
02:06 ET | 600 | 1.7 |
02:08 ET | 5460 | 1.7 |
02:09 ET | 2918 | 1.7 |
02:11 ET | 500 | 1.7 |
02:13 ET | 3500 | 1.695 |
02:15 ET | 2900 | 1.7 |
02:18 ET | 20131 | 1.705 |
02:20 ET | 10193 | 1.7099 |
02:22 ET | 1500 | 1.71 |
02:24 ET | 3777 | 1.71 |
02:26 ET | 11120 | 1.7087 |
02:27 ET | 34414 | 1.715 |
02:29 ET | 76600 | 1.715 |
02:31 ET | 4257 | 1.72 |
02:33 ET | 15980 | 1.72 |
02:36 ET | 1100 | 1.72 |
02:38 ET | 2974 | 1.72 |
02:40 ET | 12300 | 1.715 |
02:42 ET | 5856 | 1.72 |
02:44 ET | 1700 | 1.72 |
02:45 ET | 17921 | 1.72 |
02:47 ET | 12834 | 1.72 |
02:49 ET | 129241 | 1.74 |
02:51 ET | 118700 | 1.74 |
02:54 ET | 1000 | 1.735 |
02:56 ET | 72411 | 1.74 |
02:58 ET | 63159 | 1.74 |
03:02 ET | 18217 | 1.7403 |
03:03 ET | 106923 | 1.76 |
03:05 ET | 49542 | 1.765 |
03:07 ET | 28786 | 1.755 |
03:09 ET | 6320 | 1.7418 |
03:12 ET | 1900 | 1.74 |
03:14 ET | 34400 | 1.75 |
03:16 ET | 32816 | 1.75 |
03:18 ET | 4300 | 1.74 |
03:20 ET | 952 | 1.745 |
03:21 ET | 100600 | 1.74 |
03:23 ET | 7452 | 1.735 |
03:25 ET | 58910 | 1.735 |
03:27 ET | 3900 | 1.74 |
03:30 ET | 202443 | 1.75 |
03:32 ET | 110688 | 1.745 |
03:34 ET | 25374 | 1.75 |
03:36 ET | 6014 | 1.745 |
03:38 ET | 6261 | 1.745 |
03:39 ET | 3100 | 1.74 |
03:41 ET | 900 | 1.745 |
03:43 ET | 4123 | 1.75 |
03:45 ET | 6585 | 1.745 |
03:48 ET | 11766 | 1.75 |
03:50 ET | 6071 | 1.745 |
03:52 ET | 38025 | 1.745 |
03:54 ET | 21045 | 1.745 |
03:56 ET | 43683 | 1.745 |
03:57 ET | 94195 | 1.74 |
03:59 ET | 91644 | 1.75 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
CytomX Therapeutics Inc | 136.4M | 8.8x | --- |
Spero Therapeutics Inc | 76.7M | 3.4x | --- |
2Seventy Bio Inc | 216.9M | -1.0x | --- |
Rigel Pharmaceuticals Inc | 160.9M | -8.1x | --- |
G1 Therapeutics Inc | 174.6M | -5.4x | --- |
Alimera Sciences Inc | 164.5M | -2.0x | --- |
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $136.4M |
---|---|
Revenue (TTM) | $119.2M |
Shares Outstanding | 77.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.15 |
EPS | $0.20 |
Book Value | $-0.70 |
P/E Ratio | 8.8x |
Price/Sales (TTM) | 1.1 |
Price/Cash Flow (TTM) | 7.3x |
Operating Margin | 9.08% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.